Shilpa Medicare (SHILPAMED) — Announcement

📢 Key Event
Shilpa Medicare appoints Dr. Uday N. Harle as CEO of Shilpa Biologicals Private Limited.

💡 Investor Takeaway
This leadership addition strengthens Shilpa Biologicals' management capabilities, potentially enhancing future growth prospects for the subsidiary and overall group.

Shilpa Medicare announced the appointment of Dr. Uday N. Harle as CEO of its wholly owned subsidiary Shilpa Biologicals Private Limited, effective 03 August 2026. The filing complies with SEBI Regulation 30 disclosure requirements and includes Dr. Harle's extensive 24-year biopharmaceutical background spanning biologics, clinical development, and global regulatory leadership across major firms.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SHILPAMED ✨ Ask AI About This

About Shilpa Medicare Limited (SHILPAMED)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹17,391.14 Cr P/E: 48.2 ROE: 12.5% ROCE: 13.4% Div Yield: 0.07%

View full SHILPAMED stock details →

📡 Get AI alerts when SHILPAMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SHILPAMED — Free

💡 Ask AI about this filing

"How does Dr. Harle's appointment impact Shilpa Biologicals' revenue growth targets?" "What specific milestones has the subsidiary set for the next 12 months?" "How does his compensation compare to industry benchmarks for biotech CEOs?"

Ask AI Free →

📊 More SHILPAMED filings

See all SHILPAMED filings →

🔥 Also filed on 3 August 2026

TEXRAIL Texmaco Rail & Engineering Limited Financial Results UNITDSPR United Spirits Limited Announcement TENNIND Tenneco Clean Air India Limited Annual Report NAZARA Nazara Technologies Limited Financial Results NOIDATOLL Noida Toll Bridge Company Limited Financial Results RBA Restaurant Brands Asia Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SHILPAMED files new disclosures

Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHILPAMED — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd